Aethlon Medical (AEMD – Research Report), the Healthcare sector company, was revisited by a Wall Street analyst today. Analyst Vernon Bernardino from H.C. Wainwright reiterated a Buy rating on the stock and has a $7.00 price target.
Vernon Bernardino has given his Buy rating due to a combination of factors surrounding Aethlon Medical’s Hemopurifier device. The recent preclinical study results, published in the journal Transplant Immunology, highlight the Hemopurifier’s potential in enhancing the perfusion of discarded donor kidneys, which could address the chronic shortage of available donor kidneys and improve outcomes for recipients by reducing complications such as delayed function and organ rejection.
Furthermore, the Hemopurifier’s demonstrated ability to remove harmful extracellular vesicles and microRNAs from perfusion fluid suggests its applications may extend beyond virology and oncology into organ transplantation. Although further evaluation is needed, the device’s potential to improve renal function in discarded kidneys is promising. Bernardino’s valuation of Aethlon Medical, with a price target of $7, is based on projected free cash flows and a weighted-average cost of capital, while acknowledging risks such as clinical trial failures and regulatory hurdles. Despite these risks, the potential applications and underappreciated capabilities of the Hemopurifier support the Buy rating.
Bernardino covers the Healthcare sector, focusing on stocks such as Aethlon Medical, Cassava Sciences, and Senseonics Holdings. According to TipRanks, Bernardino has an average return of 2.9% and a 23.94% success rate on recommended stocks.